Johnson & Johnson (NYSE:JNJ) Reports 1Q18 Profit Up 13%; Beats Street View

Chickasaw Capital Management Lowered By $399625 Its Johnson & Johnson (JNJ) Position; Kcm Investment Advisors

Chickasaw Capital Management Lowered By $399625 Its Johnson & Johnson (JNJ) Position; Kcm Investment Advisors

It has change of 0.04, from 2017Q3's 0.83. Lenox Wealth Management Inc. now owns 1,457 shares of the company's stock valued at $193,000 after buying an additional 24 shares during the period.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Tuesday, January 23rd. The hedge fund held 275,103 shares of the major pharmaceuticals company at the end of 2017Q4, valued at $38.44M, down from 285,938 at the end of the previous reported quarter. Osher Van De Voorde Invest Mngmt, a California-based fund reported 62,072 shares. Analysts are estimating earnings per share of $8.10 for JNJ in 2018.

Shares in the Dow-component were up 1.1 percent to $133.25 before the bell.

Johnson & Johnson (JNJ) stock price moved 2.08% away from 20-Days Simple Moving Average, 1.03% from 50-Days Simple Moving Average and separated -2.63% from 200 Days Simple Moving Average. Farmers Tru reported 2.91% in Johnson & Johnson (NYSE:JNJ). South State Corporation has invested 2.46% in Johnson & Johnson (NYSE:JNJ). Trustmark Bank Department has 46,811 shares. Sabal Tru Com holds 3.31% or 232,164 shares. New Jersey Better Educational Savings Tru reported 15,000 shares. 281.53 million shares or 1.04% more from 278.63 million shares in 2017Q3 were reported. Etrade Cap Lc holds 64,275 shares.

Excluding $1 billion in write-downs on the value of assets and $300 million in other one-time charges, adjusted income came to $5.64 billion, or $2.06, a nickel better than expected. Five analysts have rated the stock with a sell rating, nine have issued a hold rating and eight have given a buy rating to the stock. Therefore 27% are positive. Johnson \u0026 Johnson had 22 analyst reports since October 18, 2017 according to SRatingsIntel. On Tuesday, January 16 the rating was maintained by Jefferies with "Buy". The company rating was maintained by Leerink Swann on Wednesday, October 18. Zacks Investment Research downgraded shares of Johnson & Johnson from a "buy" rating to a "hold" rating in a research report on Monday, April 9th. Jefferies Group set a $153.00 price objective on shares of Johnson & Johnson and gave the stock a "buy" rating in a research report on Friday. The firm has "Sell" rating given on Tuesday, January 23 by BTIG Research. Finally, Morgan Stanley lowered their target price on shares of Johnson & Johnson from $148.00 to $143.00 and set an "equal weight" rating on the stock in a report on Tuesday, April 10th. The stock has "Buy" rating by Cowen & Co on Friday, October 6. The rating was maintained by Credit Suisse with "Buy" on Thursday, October 19. Johnson & Johnson presently has a consensus rating of "Hold" and a consensus target price of $144.03. JNJ has 6.38 million shares volume. Johnson & Johnson had a net margin of 1.70% and a return on equity of 29.00%. It has underperformed by 10.43% the S&P500.

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. $353.47B is the MC of Johnsn&Johnsn.

Beyond the drug division, the consumer division and medical device division continue to post modest gains that should support continued long-term growth for Johnson & Johnson. It has a 273.71 P/E ratio. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Notícias recomendadas

We are pleased to provide this opportunity to share information, experiences and observations about what's in the news.
Some of the comments may be reprinted elsewhere in the site or in the newspaper.
Thank you for taking the time to offer your thoughts.